Allergic Rhinitis - Drug Pipeline Landscape, 2023

Allergic Rhinitis - Drug Pipeline Landscape, 2023

Allergic rhinitis (hay fever) is an allergic reaction that causes sneezing, congestion, itchy nose and sore throat. Pollen, pet dander, mold and insects can lead to hay fever symptoms. It is strongly linked to asthma and conjunctivitis.

Allergic rhinitis occurs when body's immune system reacts to an irritant in the air. Seasonal and perennial allergies can result from many allergens, including dust mites, pollen, pet dander, mold spores and cockroaches

The classic symptoms of the disorder are nasal congestion, nasal itch, rhinorrhea, sneezing, itchy eyes, watery eyes, dark circles under the eyes and frequent headaches.

Diagnosis of allergic rhinitis include thorough history, physical examination and allergen skin testing. To measure antibodies to specific allergens, provider may take a blood sample and send it to a lab for testing. This blood test is called an immunoglobulin E (IgE) test. It can detect all types of allergies, including food allergies. Healthcare provider may recommend a skin prick test to determine what allergens are causing your symptoms.

Treatments for allergic rhinitis include antihistamines, decongestants, eye drops and nasal sprays, immunotherapy, sublingual immunotherapy (SLIT).

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Allergic Rhinitis treatment such as AI201901, MG01/T517, MM09 and others. Key players involved in the development of therapies to treat Allergic Rhinitis are Abdi Ibrahim Ilac San, Inmunotek S.L, Paradigm Biopharmaceuticals Ltd, Allergy Therapeutics, Regeneron Pharmaceuticals and others. Ten drugs are under late-stage Phase III clinical trials, six drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.

Report Highlights

Global Insight Service's, Allergic Rhinitis - Drug Pipeline Landscape, 2023 report provides an overview of the Allergic Rhinitis pipeline drugs. This report covers detailed insights on Allergic Rhinitis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Allergic Rhinitis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.